Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Verastem Oncology (NASDAQ: VSTM) has recently announced positive updated safety and efficacy results from the ramp 205 phase 1/2 trial, which is evaluating avutometinib plus defactinib in combination ...

Incyte Corp. has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, as well as autoimmune and inflammatory disorders.

Eli Lilly and Company today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

Belvidere, New Jersey, U.S.A.-based sustainable agriculture company Edible Garden has acquired assets – including ...

Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase 3 RAMP-301 clinical trial.

The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.